Signaturefd LLC Has $159,000 Stock Position in Fresenius Medical Care AG (NYSE:FMS)

Signaturefd LLC trimmed its position in Fresenius Medical Care AG (NYSE:FMS) by 11.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,643 shares of the company’s stock after selling 958 shares during the quarter. Signaturefd LLC’s holdings in Fresenius Medical Care were worth $159,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bruce G. Allen Investments LLC purchased a new stake in shares of Fresenius Medical Care in the fourth quarter worth approximately $31,000. Hartford Financial Management Inc. lifted its position in shares of Fresenius Medical Care by 98.8% in the fourth quarter. Hartford Financial Management Inc. now owns 1,688 shares of the company’s stock worth $35,000 after purchasing an additional 839 shares in the last quarter. Morningstar Investment Services LLC lifted its position in shares of Fresenius Medical Care by 6.4% in the third quarter. Morningstar Investment Services LLC now owns 10,145 shares of the company’s stock worth $220,000 after purchasing an additional 612 shares in the last quarter. Advisor Partners II LLC lifted its position in shares of Fresenius Medical Care by 16.3% in the third quarter. Advisor Partners II LLC now owns 10,836 shares of the company’s stock worth $233,000 after purchasing an additional 1,518 shares in the last quarter. Finally, Clearbridge Investments LLC lifted its position in shares of Fresenius Medical Care by 21.7% in the third quarter. Clearbridge Investments LLC now owns 11,106 shares of the company’s stock worth $239,000 after purchasing an additional 1,981 shares in the last quarter. 8.25% of the stock is currently owned by institutional investors and hedge funds.

Fresenius Medical Care Price Performance

Shares of FMS opened at $20.10 on Monday. The firm has a market cap of $11.80 billion, a PE ratio of 21.85, a PEG ratio of 1.10 and a beta of 1.00. The firm’s 50 day moving average price is $19.51 and its 200 day moving average price is $19.47. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.07 and a current ratio of 1.42. Fresenius Medical Care AG has a twelve month low of $16.37 and a twelve month high of $27.72.

Fresenius Medical Care (NYSE:FMS) last issued its quarterly earnings data on Tuesday, February 20th. The company reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of $0.36 by $0.11. Fresenius Medical Care had a net margin of 2.56% and a return on equity of 4.99%. The business had revenue of $5.37 billion during the quarter, compared to analysts’ expectations of $5.32 billion. As a group, research analysts expect that Fresenius Medical Care AG will post 1.51 EPS for the current fiscal year.

Fresenius Medical Care Cuts Dividend

The company also recently disclosed an annual dividend, which will be paid on Monday, June 3rd. Stockholders of record on Monday, May 20th will be paid a $0.437 dividend. This represents a dividend yield of 2.35%. The ex-dividend date is Friday, May 17th. Fresenius Medical Care’s payout ratio is 46.74%.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on FMS shares. StockNews.com started coverage on shares of Fresenius Medical Care in a research report on Friday. They set a “strong-buy” rating on the stock. Morgan Stanley lowered shares of Fresenius Medical Care from an “equal weight” rating to an “underweight” rating in a research report on Monday, January 8th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $32.25.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.